[
  {
    "ts": "2025-11-19T11:42:49+00:00",
    "headline": "1 Cash-Heavy Stock with Solid Fundamentals and 2 We Ignore",
    "summary": "Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.",
    "url": "https://finance.yahoo.com/news/1-cash-heavy-stock-solid-114249351.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "a9d947fb-8287-3990-b05e-aeba1862aad7",
      "content": {
        "id": "a9d947fb-8287-3990-b05e-aeba1862aad7",
        "contentType": "STORY",
        "title": "1 Cash-Heavy Stock with Solid Fundamentals and 2 We Ignore",
        "description": "",
        "summary": "Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.",
        "pubDate": "2025-11-19T11:42:49Z",
        "displayTime": "2025-11-19T11:42:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/01c0d1c16bdd25e7a9cedd6876d4a4bf",
          "originalWidth": 2400,
          "originalHeight": 1600,
          "caption": "CRM Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9nXBHcOwQGrE0Ede4AMlpw--~B/aD0xNjAwO3c9MjQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/stockstory_922/01c0d1c16bdd25e7a9cedd6876d4a4bf.cf.webp",
              "width": 2400,
              "height": 1600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8uckGKhbZ14_uv.rJPMIQQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/01c0d1c16bdd25e7a9cedd6876d4a4bf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/1-cash-heavy-stock-solid-114249351.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-cash-heavy-stock-solid-114249351.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "FSUN"
            },
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "CRM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-19T21:00:00+00:00",
    "headline": "Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3",
    "summary": "BOSTON, November 19, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in Citi’s 2025 Global Healthcare Conference. Charlie Wagner, Chief Operating and Financial Officer, and David Altshuler, Chief Scientific Officer, will participate in a fireside chat on Wednesday, December 3, 2025, at 9:00 a.m. ET.",
    "url": "https://finance.yahoo.com/news/vertex-participate-citi-2025-global-210000763.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "e86e5b1b-495f-30c0-b50b-75e63b86f632",
      "content": {
        "id": "e86e5b1b-495f-30c0-b50b-75e63b86f632",
        "contentType": "STORY",
        "title": "Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3",
        "description": "",
        "summary": "BOSTON, November 19, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in Citi’s 2025 Global Healthcare Conference. Charlie Wagner, Chief Operating and Financial Officer, and David Altshuler, Chief Scientific Officer, will participate in a fireside chat on Wednesday, December 3, 2025, at 9:00 a.m. ET.",
        "pubDate": "2025-11-19T21:00:00Z",
        "displayTime": "2025-11-19T21:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/eecca8a21b91a3473bf693d01df20f45",
          "originalWidth": 480,
          "originalHeight": 252,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AgVroAHne1kLkXQE9xfAPw--~B/aD0yNTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/eecca8a21b91a3473bf693d01df20f45.cf.webp",
              "width": 480,
              "height": 252,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wedROIB1TgJ1OLPBehaKAg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/eecca8a21b91a3473bf693d01df20f45.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-participate-citi-2025-global-210000763.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-participate-citi-2025-global-210000763.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-19T20:42:21+00:00",
    "headline": "This Leading Gene-Editing Stock Could Be Going Private. Should You Buy Its Shares First?",
    "summary": "CRISPR Therapeutics is the subject of strong buyout speculation after earning FDA approval for a breakthrough gene-editing therapy.",
    "url": "https://www.barchart.com/story/news/36214924/this-leading-gene-editing-stock-could-be-going-private-should-you-buy-its-shares-first",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "2f0028db-b08a-3e79-9ffa-4162d2136985",
      "content": {
        "id": "2f0028db-b08a-3e79-9ffa-4162d2136985",
        "contentType": "STORY",
        "title": "This Leading Gene-Editing Stock Could Be Going Private. Should You Buy Its Shares First?",
        "description": "",
        "summary": "CRISPR Therapeutics is the subject of strong buyout speculation after earning FDA approval for a breakthrough gene-editing therapy.",
        "pubDate": "2025-11-19T20:42:21Z",
        "displayTime": "2025-11-19T20:42:21Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/d3b0735997823ab2c69af690f505d319",
          "originalWidth": 1600,
          "originalHeight": 1068,
          "caption": "Buy enter button by Ardasavasciogullari via iStock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lrfQGDC_bat0PzQZ6QoCfQ--~B/aD0xMDY4O3c9MTYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/barchart_com_477/d3b0735997823ab2c69af690f505d319.cf.webp",
              "width": 1600,
              "height": 1068,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AJ.tY9YwnPi1S3tD3bIJuw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/d3b0735997823ab2c69af690f505d319.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/36214924/this-leading-gene-editing-stock-could-be-going-private-should-you-buy-its-shares-first",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/leading-gene-editing-stock-could-204221928.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRSP"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]